Pharsight

Ztlido patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10765640 SCILEX PHARMS INC Non-aqueous patch
May, 2031

(7 years from now)

US9931403 SCILEX PHARMS INC Non-aqueous patch
May, 2031

(7 years from now)

US10765749 SCILEX PHARMS INC Non-aqueous patch
May, 2031

(7 years from now)

US11278623 SCILEX PHARMS INC Non-aqueous patch
May, 2031

(7 years from now)

US9925264 SCILEX PHARMS INC Non-aqueous patch
May, 2031

(7 years from now)

US9283174 SCILEX PHARMS INC Non-aqueous patch
May, 2031

(7 years from now)

Ztlido is owned by Scilex Pharms Inc.

Ztlido contains Lidocaine.

Ztlido has a total of 6 drug patents out of which 0 drug patents have expired.

Ztlido was authorised for market use on 28 February, 2018.

Ztlido is available in patch;topical dosage forms.

Ztlido can be used as method for relieving the pain associated with post-herpetic neuralgia.

The generics of Ztlido are possible to be released after 10 May, 2031.

Drugs and Companies using LIDOCAINE ingredient

Market Authorisation Date: 28 February, 2018

Treatment: Method for relieving the pain associated with post-herpetic neuralgia

Dosage: PATCH;TOPICAL

How can I launch a generic of ZTLIDO before it's drug patent expiration?
More Information on Dosage

ZTLIDO family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic